In recent months, a heated debate has emerged in the cannabis industry over the necessity of stringent microbial testing standards. Specifically, the testing for Aspergillus—a genus of mold that includes species such as Aspergillus niger, Aspergillus flavus, Aspergillus fumigatus, and Aspergillus terreus—has taken center stage. This debate intensified when Glass House Farms, one of California’s largest cannabis cultivators, faces an August, 2024, recall due to the presence of Aspergillus flavus in a batch of their pre-rolled products.
Aspergillus is not an abstract concern. The risks associated with these fungi are very real, particularly when inhaled through contaminated cannabis products. Aspergillus flavus is known to produce aflatoxins, potent carcinogens, while A. niger can cause respiratory issues and invasive infections, particularly in immunocompromised individuals.
In particular, Aspergillus flavus harbors aflatoxins.
Understanding the Science Behind Aspergillus Contamination
Aspergillus species are ubiquitous in the environment, often found in soil, compost, and organic material. However, just because they are commonly present doesn’t mean they’re safe. In fact, inhalation of Aspergillus spores, particularly from cannabis products, can pose serious health risks, including:
- Allergic Reactions: Ranging from mild to severe, particularly affecting those with asthma or other respiratory conditions.
- Infections: While rare, invasive aspergillosis can occur in immunocompromised individuals, leading to life-threatening conditions. This is particularly concerning for medical cannabis users with underlying health issues.
- Mycotoxins: Some Aspergillus strains produce dangerous mycotoxins, such as aflatoxins, which are linked to liver cancer and other severe diseases.
Despite these dangers, some in the industry argue that eliminating Aspergillus entirely from cannabis is impossible and unnecessary. In California, however, the Department of Cannabis Control (DCC) mandates that cannabis products, especially inhalables, be completely Aspergillus-free. Failure to comply with these regulations results in mandatory recalls, as Glass House Farms recently discovered.
The Importance of Testing and the Glass House Controversy
Glass House Farms, boasting one of the largest greenhouse operations in California, recently announced it would appeal the recall by the DCC over Aspergillus flavus contamination in their Garlic Starship pre-rolls. The company claims that despite double-testing their products, the DCC provided minimal information regarding the recall, leading to frustration and uncertainty about the source of contamination.
This situation has highlighted the ongoing tension between cultivators and regulators. Massive companies like Glass House Farms argue it is nearly impossible to ensure that no Aspergillus spores are present in a batch, especially when they are so prevalent in the environment. However, regulators maintain that consumer safety must remain the top priority, especially when the health risks associated with Aspergillus are so well-documented.
Why the DCC Issues Recalls
The Department of Cannabis Control (DCC) does not issue recalls lightly. A recall typically happens when a cannabis product fails to meet California’s strict safety standards, which are in place to protect consumers from potentially harmful contaminants. These contaminants include pathogenic Aspergillus species, Salmonella, Shiga toxin-producing E. coli, and other dangerous microbes. If a product fails microbial or mycotoxin testing, or if it poses a health risk to the public, the DCC steps in with a mandatory recall to prevent harm.
The DCC’s mission is clear: ensure that the cannabis sold in California is safe for consumption—whether for medical or recreational use.
Why Testing Standards Matter
The science is clear: contaminated cannabis products can have serious health repercussions, especially for those who are vulnerable. The California DCC’s testing requirements for pathogenic Aspergillus species are designed to protect consumers from these risks. According to California regulations, cannabis products must pass rigorous microbial and mycotoxin testing before they can be sold. The rules state:
- Microbial Testing: Cannabis must be free from pathogenic Aspergillus species (A. fumigatus, A. flavus, A. niger, and A. terreus), Salmonella spp., and Shiga toxin-producing Escherichia coli.
- Mycotoxin Testing: Aflatoxins and ochratoxin must not exceed the safety limits of 20 µg/kg.
These regulations are in place for a reason. Consumers should not have to worry about whether their medicine or recreational product could cause harm. Rolling back these standards would be a step backward for consumer safety, and it’s imperative that the industry uphold these protections, especially as the market continues to expand.
What is qPCR, and Why is it Used in Cannabis Testing?
It’s not completely clear from the information currently available at press-time what the actual protocols used by the analytical testing lab contracted by Glass House Farms were, but Glass House representatives have mentioned qPCR, so in the interest of better understanding, let’s get into what “qPCR” is supposed to work.
Quantitative Polymerase Chain Reaction (qPCR) is a powerful and precise molecular technique used to detect the presence of specific DNA sequences in a sample. In the context of cannabis testing, qPCR is employed to detect microbial contaminants like Aspergillus, which can be harmful when inhaled. This method is particularly valuable because it can identify pathogens at a very low concentration, even before they start producing toxins or causing visible spoilage.
qPCR works by amplifying the DNA of the target organism—such as Aspergillus niger or Aspergillus flavus—to detectable levels. The method uses fluorescent markers to measure the amount of DNA present as the amplification progresses. This allows labs to quantify how much of a particular microbe is in a sample and determine if it exceeds safety thresholds.
While qPCR is highly sensitive and specific, one common critique is that it can detect even dormant spores or dead cells, raising questions about whether these findings represent an actual health risk. However, in the interest of consumer safety, regulatory bodies like the DCC err on the side of caution, requiring products that test positive for pathogenic DNA to be recalled or remediated. This ensures that any potential health threat—whether from viable or non-viable spores—is eliminated before the product reaches the consumer.
What’s Next? A Call to Action for Stakeholders
The challenges facing the cannabis industry are not new. Balancing growth, regulation, and consumer safety has always been a struggle for many sectors. However, the stakes are higher than ever as cannabis becomes more mainstream, and the risks associated with contaminated products grow.
As stakeholders in the cannabis industry, it is our responsibility to prioritize safety over profits. Companies like Glass House should focus on improving their processes to ensure compliance with safety regulations rather than seeking to weaken those standards. In the end, maintaining high-quality, safe products will build trust with consumers and contribute to the long-term success of the industry.
Conclusion
The case of Glass House Farms brings critical issues to light regarding Aspergillus testing and the broader cannabis industry’s commitment to quality control. As consumers and advocates for safety, we must hold companies accountable and demand that they meet the necessary health standards. For those of us who rely on cannabis for medicinal purposes, this is not just a matter of business—it’s a matter of life and death.
Leave a Reply